Skip to main content
Premium Trial:

Request an Annual Quote

InterVenn Biosciences: John Leite

John Leite has become chief business officer at InterVenn Biosciences, based in South San Francisco. Previously, he was VP of oncology, market development, and product marketing for Illumina's oncology business. Prior to that, he was VP of commercial strategy and market access for Genoptix, and earlier in his career, he was a scientist at Invitrogen. Leite holds a PhD in biochemistry from the University of Pittburgh School of Medicine.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.